The trial was a randomised, double-blind, placebo-controlled study in 150 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of GLP-1 analogue, for a combination treatment period of 4 weeks with a 5-month follow-up.
Following the result of the trial, Transition Therapeutics has decided to terminate the development of TT-223.
Transition Therapeutics said that the diabetes compounds that it has in-licensed from Lilly act through a distinctly different mechanism of action from gastrin based therapies.